GSK application to expand use of Nucala for COPD accepted for review by EMA Ruchika Sharma25 March 2025 1:30 PM ISTIL-5 is a key cytokine (protein) in type 2 inflammation which is an underlying driver in many diseases.
GSK Nucala application for COPD accepted for review in China Ruchika Sharma23 Feb 2025 12:30 PM ISTGSK plc has announced that the China National Medical Products Administration has accepted for review the new drug application for the use of...
GSK Pharma's Q3 Profit Jumps 35% on Strong Demand for Augmentin, Respiratory Drugs Farhat Nasim16 Feb 2025 11:45 AM ISTBengaluru: India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its...
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma4 Jan 2025 1:00 PM ISTLondon: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody...
USFDA accepts GSK submission for use of Nucala in COPD Ruchika Sharma11 Dec 2024 11:30 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the...
GSK announces positive results from phase III trial of Nucala in COPD Ruchika Sharma8 Sept 2024 1:30 PM ISTLondon: GSK plc has announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) a...
GSK Nucala approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma3 Sept 2024 4:19 PM ISTGSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Nucala (mepolizumab), a monoclonal antibody that...
Submit details of adverse events reported: CDSCO Panel Tells GSK on Mepolizumab Powder for Solution for Injection Dr. Divya Colin24 Aug 2024 6:00 PM ISTNew Delhi: In line with the Phase IV clinical trial report of the monoclonal antibody Mepolizumab (Brand Name: Nucala 100 mg) presented by the drug...
GSK Nucala approved in China for use in severe asthma with eosinophilic phenotype Ruchika Sharma12 Jan 2024 11:35 AM ISTLondon: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on...
GSK regulatory submission accepted for review by Japanese regulator for Nucala use in adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma3 Sept 2023 12:45 PM ISTLondon: GSK plc has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted for review a supplementary new drug...
No USFDA approval for AstraZeneca's treatment for chronic nasal condition MD Bureau15 March 2022 3:02 PM ISTThe London-listed drugmaker said the U.S. Food and Drug Administration (FDA) had issued a complete response letter following AstraZeneca's application...
FDA approves Nucala as add-on treatment for chronic rhinosinusitis patients with nasal polyps Hina Zahid2 Aug 2021 9:00 AM ISTThe US Food and Drug Administration (FDA) has approved Nucala as a treatment for adults who have chronic rhinosinusitis with nasal polyps. Nucala...
